• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Join the Alliance

The International Alliance of ALS/MND Associations encourages all organizations involved in support of people living with ALS/MND or have an interest in ALS/MND to apply for membership.

The Alliance offers three types of membership: Full, Affiliate, and Honorary. Each has its own criteria, application requirements, and fees.

Membership Criteria, Application Requirements & Fees

Full Membership

To qualify for Full Membership, an organization must:

  • Serve people with ALS/MND or related disorders with a focus on patient care, advocacy and/or research;
  • Be chartered in their own country as a non-profit national or independent organization for at least 2 years;
  • Have a legal constitution or by-laws;
  • Be governed by a volunteer Board of Directors (however described), elected by and/or from the membership which includes people living with ALS/MND, carers, past carers, or people closely associated with the disease; and
  • Prepare an annual financial statement.

Applicants for Full Membership must submit the following documents in English:

  • Cover letter stating their reasons for wanting to become a member of the Alliance
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement of the organization
  • Written financial statement of previous year’s income
  • Copies of or weblinks to brochures and other materials (if not in English, then with some English translation)

The fee for Full Membership is either an amount equal to 0.2% of total annual income of the applicant organization or £100 (Pounds Sterling), whichever is greater. At the discretion of the Board of Trustees, fees can be waived or reduced for members that demonstrate need and make a request in writing.

Affiliate Membership

Affiliate Membership in the Alliance falls within four categories:

  1. Emerging Associations Affiliate: New ALS/MND Associations being established or recently chartered in own country as a non-profit organization (or status pending) by July 1st of the current membership year.
  2. Network Affiliate:
    1. Regional non-profit networks of researchers and clinicians collaborating on ALS/MND
    2. Regional non-profit patient networks providing resources and support to people living with ALS/MND
    3. Non-profit neurological alliances advocating for and supporting people with neurological conditions
  3. Education and Research Affiliate: Education or research institutes and centres dedicated to ALS/MND that operate within a non-profit entity such as a university.
  4. Fiscal Sponsorship/Hosting Arrangement Affiliate: Organizations focused on ALS/MND that are not independently chartered and operate under the legal or administrative framework of a sponsoring or host organization.

To qualify for Affiliate Membership, an organization must:

  • Serve people with ALS/MND or related disorders with a focus on patient care, advocacy and/or research;
  • Be formally established in their own country as a non-profit organization, operate within a non-profit entity, or function under the legal or administrative structure of a sponsoring/host organization;
  • Be governed directly or indirectly by a legal constitution or by-laws;
  • Be governed by a volunteer Board of Directors (however described), elected by and/or from the membership that includes people living with ALS/MND, carers, past carers, or people closely associated with the disease; and
  • Prepare an annual financial statement (where administratively relevant).

Applicants for Affiliate Membership must submit the following documents in English:

  • Cover letter stating their reasons for wanting to become a member of the Alliance
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement of the organization
  • Written financial statement of previous year’s income (only for Emerging Associations, if available, and Network Affiliates)
  • Copies of or weblinks to brochures and other materials (if not in English, then with some English translation)

The fee for Affiliate Membership is £100 (Pounds Sterling). At the discretion of the Board of Trustees, fees can be waived or reduced for members that demonstrate need and make a request in writing.

Honorary Membership

Honorary Membership is awarded at the discretion of the Alliance’s Board of Trustees to individuals who have made significant contributions to the Alliance’s mission of a world free of ALS/MND. This may include former Board Members, Patrons, Staff, or Award recipients.

 

For any questions or to apply for membership, please contact the CEO at alliance@als-mnd.org.

The Board reviews applications quarterly. You will be notified of the decision by email.

We encourage prospective members to attend the Alliance Meeting. Observer status will be granted.

Primary Sidebar

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Willi Klein, UK

    Willi Klein, UK

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Bob Simonds, USA

    Bob Simonds, USA

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Jean Waters, UK

    Jean Waters, UK

  • Ian Roberts, Australia

    Ian Roberts, Australia

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Daniel Hare, USA

    Daniel Hare, USA

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Zabun Nassar, England

    Zabun Nassar, England

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Maria Lucia Wood Saldanha, Brazil

    Maria Lucia Wood Saldanha, Brazil

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Frank Taylor, USA

    Frank Taylor, USA

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Seckin McGuirk, England

    Seckin McGuirk, England

  • Monica Soriano, Argentina

    Monica Soriano, Argentina

  • Denis Blais, Canada

    Denis Blais, Canada

  • Jason Goodman, USA

    Jason Goodman, USA

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Feng Gin Sun, China

    Feng Gin Sun, China

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Enzo Maccarrone, Italy

    Enzo Maccarrone, Italy

  • H. Todd Kelly, USA

    H. Todd Kelly, USA

  • Anthony Lynch, Australia

    Anthony Lynch, Australia

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Anna Barrow, UK

    Anna Barrow, UK

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • John Sweeney, USA

    John Sweeney, USA

  • Olga, Argentina

    Olga, Argentina

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Shera Mukherjee, India

    Shera Mukherjee, India

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login